Biogen AI Stock Analysis
Want to see BIIB full AI Analyst Report?
Biogen (BIIB) AI Stock Analysis
Biogen
(NASDAQ:BIIB)
BIIB’s score is driven primarily by steady but pressured financial performance (solid cash flow and manageable leverage, offset by a clear TTM margin/FCF downshift). Technicals add support with strong trend strength above major moving averages, though momentum looks extended. The most significant drag is valuation (high P/E), while the earnings call meaningfully improves the outlook via raised EPS guidance, strong growth-portfolio momentum, and synergy/deleveraging progress.
Biogen Key Performance Indicators (KPIs)
Revenue by GeographyBreaks down Biogen’s sales across regions, showing where its drugs earn the most revenue and where growth or regulatory risk is concentrated. Useful for spotting heavy reliance on the U.S. market, exposure to differing reimbursement rules, and which regions offer room to expand with new approvals or label changes.
International revenue shows a multi‑year erosion with intermittent rebounds and a pronounced late‑2025 trough—consistent with ex‑U.S. shipment timing and biosimilar/access pressure (TYSABRI) noted on the call—while the “Other” geography bucket has meaningfully strengthened into 2026 as Biogen’s growth portfolio and the Apellis assets begin contributing. The company’s guidance upgrade hinges on that mix shift: acquisitions and new product adoption offset regional weakness, but near‑term EPS and leverage risks persist until synergies and broader payer access (e.g., IQLIK, SPINRAZA high‑dose) materialize.
Biogen (BIIB) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $37.07B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.08M
- Price to Earnings (P/E)
- 105.6
- Beta (1Y)
- 0.46
- Revenue Growth
- 2.15%
- EPS Growth
- -78.55%
- Country
- US
- Employees
- 7,500
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - General
Biogen Business Overview & Revenue Model
Company Description
Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addre...
How the Company Makes Money
Biogen makes money primarily by selling prescription medicines and recognizing revenue from collaboration-related arrangements. 1) Product sales (core revenue stream) - Biogen’s largest revenue driver is net sales of its marketed therapies. This incl...
Biogen Earnings Call Summary
The call was strongly positive overall. Biogen reported double-digit revenue growth, accelerating growth-portfolio performance, rapid Appellis synergy capture, strong adoption of key products, record early-stage pipeline productivity, solid free cash flow, debt repayment, and higher 2026 EPS guidance. The main challenges were VUMERITY's formulary-driven decline, acquisition-related charges and higher operating expenses, expected Q4 inventory and revenue normalization, SYFOVRE discontinuation levels, and uncertainty around upcoming clinical readouts.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Biogen expects to return to top line growth in 2026; full year 2026 non-GAAP diluted EPS guidance is between $12.20 and $13.00, with approximately $50 million of acquired IPR&D in the fourth quarter. Q4 global SPINRAZA revenue is expected to be up approximately a mid single digit percentage versus the fourth quarter of 25, Q4 VUMERITY revenue is expected to be roughly flat sequentially or up approximately a mid single digit percentage versus the fourth quarter of 25, and Q4 SYFOVRE revenue is expected to be up approximately a mid single digit percentage versus the $155 million reported by Appellis in the fourth quarter of 25; SKYCLARYS inventory of approximately $12 million and SYFOVRE inventory of approximately $11 million are expected to be drawn down in Q4. The Appellis transaction is expected to be less dilutive in 2026 and accretive to non GAAP diluted EPS in 2027, generating at least $250 million of run rate synergies by the end of 2027, while Biogen expects to repay the remaining $1.4 billion of term loans by the end of 27; at least 50% of covered lives are expected to have coverage for LEQEMBI iClick in both the initiation and maintenance administrations starting in 2027.
Biogen Financial Statement Overview
Summary
Financials are mixed: revenue is modestly higher in TTM (~3.5%) and cash generation remains solid (TTM operating cash flow ~$2.25B; free cash flow ~$2.42B, ~1.03x net income). However, profitability has weakened meaningfully versus prior years (TTM net margin ~8.4% and EBITDA margin ~19.7%), and free cash flow is down (~18% YoY). Leverage looks manageable (debt-to-equity ~0.44), but ROE has cooled (~4.5%), reflecting the margin downshift.
Income Statement
62PositiveBalance Sheet
70PositiveCash Flow
68Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.30B | 9.89B | 9.68B | 9.84B | 10.17B | 10.98B |
| Gross Profit | 7.21B | 7.49B | 7.37B | 7.30B | 7.90B | 8.87B |
| EBITDA | 1.60B | 2.60B | 3.00B | 2.38B | 3.54B | 3.92B |
| Net Income | 347.50M | 1.29B | 1.63B | 1.16B | 3.05B | 1.56B |
Balance Sheet | ||||||
| Total Assets | 32.05B | 29.44B | 28.05B | 26.84B | 24.55B | 23.88B |
| Cash, Cash Equivalents and Short-Term Investments | 1.30B | 3.82B | 2.38B | 1.05B | 4.89B | 3.80B |
| Total Debt | 7.80B | 6.95B | 6.63B | 7.34B | 6.61B | 7.60B |
| Total Liabilities | 13.13B | 11.18B | 11.33B | 12.05B | 11.17B | 12.92B |
| Stockholders Equity | 18.92B | 18.26B | 16.72B | 14.80B | 13.40B | 10.90B |
Cash Flow | ||||||
| Free Cash Flow | 2.05B | 2.05B | 2.52B | 1.24B | 1.14B | 3.38B |
| Operating Cash Flow | 2.25B | 2.20B | 2.88B | 1.55B | 1.38B | 3.64B |
| Investing Cash Flow | -5.50B | -1.37B | -799.20M | -4.09B | 1.59B | -563.70M |
| Financing Cash Flow | 776.60M | -301.90M | -683.50M | 137.00M | -1.76B | -2.09B |
Biogen Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIIB, the sentiment is Positive. The current price of 250.79 is above the 20-day moving average (MA) of 250.52, above the 50-day MA of 234.73, and above the 200-day MA of 205.87, indicating a bullish trend. The MACD of 4.90 indicates Positive momentum. The RSI at 56.04 is Neutral, neither overbought nor oversold. The STOCH value of 56.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BIIB.
Biogen Risk Analysis
Biogen disclosed 30 risk factors in its most recent earnings report. Biogen reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
1 New RiskBiogen Peers Comparison
Overall Rating
SNY83Outperform
LLY81Outperform
NVS72Outperform
ABBV71Outperform
JNJ70Outperform
BIIB67Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 83Outperform | $114.16B | 24.80 | 5.84% | 5.09% | 23.68% | -30.90% | |
| 81Outperform | $1.33T | 45.54 | 83.65% | 0.49% | 45.51% | 50.48% | |
| 72Outperform | $290.32B | 30.52 | 24.24% | 2.98% | 1.64% | -28.72% | |
| 71Outperform | $517.59B | 50.06 | -202.35% | 2.36% | 10.68% | 338.08% | |
| 70Outperform | $670.92B | 42.30 | 19.55% | 1.89% | 7.81% | -35.95% | |
| 67Neutral | $37.07B | 105.59 | 1.86% | ― | 2.15% | -78.55% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BIIB | Biogen Inc. | 250.79 | 82.61 | 49.12% | |
| LLY | Eli Lilly And Company | 1415.55 | 378.53 | 36.50% | |
| JNJ | Johnson & Johnson | 278.70 | 80.11 | 40.34% | |
| NVS | Novartis AG | 159.13 | 37.16 | 30.46% | |
| SNY | Sanofi SA | 47.53 | 0.52 | 1.10% | |
| ABBV | Abbvie | 292.82 | 70.04 | 31.44% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 28, 2026
